Skip Navigation

Judy E. Garber, MD, MPH

Medical Oncology

Make an Appointment
Watch Video


  • Director, Center for Cancer Genetics and Prevention
  • Susan F. Smith Chair
  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Clinical Interests

  • Breast cancer
  • Cancer genetics
  • Cancer prevention

Diseases Treated

Contact Information

  • Appointments(617) 632-2178
  • Office Phone Number617-632-2178 (Cancer Genetics and Prevention)
    617-632-3800 (Breast Oncology)
  • Fax617-582-8807


Dr. Garber is the Director of the Center for Cancer Genetics and Prevention at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. She conducts research in clinical cancer genetics, with a special focus in the genetics of breast cancer. She has played a major role in the development of national guidelines in cancer genetics. Dr. Garber is also a leader in research into the characteristics and treatment of triple negative or basal-like breast cancer, the most common form in women with BRCA1 mutations. Her translational research focuses on the evaluation of novel agents targeting DNA repair defects in breast cancer, including PARP inhibitors for treatment and prevention of breast cancer and other BRCA-associated cancers.

Dr. Garber is a past president and current member of the Foundation Board of the American Association for Cancer Research (AACR). She serves on the National Cancer Advisory Board of the National Cancer Institute and was elected into the National Academy of Medicine in 2013. She also serves as the Chair of the Breast Cancer Research Foundation (BCRF) Scientific Advisory Board. She is an ASCO Statesman and a Fellow of the AACR Academy.

Board Certification:

  • Hematology, 1988
  • Internal Medicine, 1984
  • Medical Oncology, 1987


  • Brigham and Women's Hospital, Hematology
  • Dana-Farber Cancer Institute, Cancer Epidemiology
  • Dana-Farber Cancer Institute, Medical Oncology


  • Brigham and Women's Hospital, Internal Medicine

Medical School:

  • Yale University School of Medicine

Recent Awards:

  • Charles H. Dyson Scholar in Clinical Research, DFCI 1997
  • Tisch Award, Dana-Farber Cancer Institute, 2007
  • ASCO Statesman Award, American Society of Clinical Oncology, 2008
  • Claire W. and Richard P. Morse Research Award, Dana-Farber Cancer Institute, 2009
  • Fellow, AACR Academy, American Association for Cancer Research, 2013
  • Member, Institute of Medicine/National Academy of Medicine, 2014
  • Margaret L. Kripke Legend Award, MD Anderson Cancer Center, 2017
  • AACR Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research, 2017
  • Umberto Veronesi IEO Breast Cancer Award, 2017


Clinical Cancer Genetics, Cancer Risk, and Prevention

Our group has two areas of active interest: the identification of individuals with genetic factors that place them at high risk of developing cancer, and the development of strategies to reduce cancer risk. We focus on breast cancer primarily, but are now expanding our efforts to other cancers. Breast cancer geneticsOur group developed one of the first cancer risk and prevention clinics, where we recruit patients and families with hereditary and familial breast cancer, evaluate them for mutations in BRCA1, BRCA2, and other genes, and then enroll patients in ongoing follow-up studies. These studies evaluate the long-term psychosocial and medical effects of genetic testing and explore the best ways to integrate genetic testing into the care of women diagnosed with breast cancer. We are also studying the prevalence of germline p53 mutations and mutations in the Fanconi anemia (FA) genes in a cohort of the very youngest women diagnosed with breast cancer. In collaboration with Dr. Alan D'Andrea, we also plan to expand epidemiologic studies of the FA genes to squamous tumors. Breast cancer risk reductionWe are developing novel approaches to the chemoprevention of cancer and the identification of modulatable biomarkers for use in chemoprevention studies. One clinical trial uses aromatase inhibitors to reduce circulating estradiol in women who have the highest levels, and measures changes in bone density and mammographic breast density as biomarkers of hormone effect. Another trial is piloting tamoxifen in women with increased risk of breast cancer because of chest radiation therapy for Hodgkin's disease. In collaboration with Drs. Myles Brown and Bruce Spiegelman, we are developing biomarker assays for use in the evaluation of rosiglitazone in an early-phase breast cancer chemoprevention trial. In a phase I chemoprevention trial, we are studying the epidermal growth factor receptor (EGFR) antagonist, Iressa. Finally, we are developing duct lavage as a sampling technique with which to identify modulatable biomarkers for use in breast cancer chemoprevention trials.PharmacogeneticsWe are also interested in using genetic markers to identify individuals at particular risk for toxic side effects of chemoprevention agents. Two large national trials are evaluating the potential contributions of hereditary clotting abnormalities, factor V Leiden and prothrombin G20210A, to the risk of thromboembolic complications with tamoxifen.


Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions